Yeah ACL has been frustrating as has chemgenex. BTA is an old hand and they had many a chance to sell out cheaply. Yet they held Laninamivir and bta798 only to progress them in trials. When they consider the deal fair they have also shown they can successfully license them out. RSV is a great example. It's an exciting year coming for BTA. Recent share price volatility has been frustrating but opened an opportunity to top up. Some directors picked up some more. BTA has a really nice portfolio and if they list on the NASDAQ I suspect the stock will be more fairly valued.
BTA Price at posting:
$1.43 Sentiment: Buy Disclosure: Held
